Connect Biopharma Holdings Limited
CNTB
$2.05
-$0.10-4.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.00K | -- | 958.50K | 958.50K | 24.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.00K | -- | 958.50K | 958.50K | 24.12M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 48.00K | -- | 958.50K | 958.50K | 24.12M |
| SG&A Expenses | 4.70M | 4.81M | 5.90M | 5.90M | 4.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 1.29M | 1.29M | -- |
| Total Operating Expenses | 13.47M | 11.45M | 15.16M | 15.16M | 9.07M |
| Operating Income | -13.42M | -11.45M | -14.20M | -14.20M | 15.05M |
| Income Before Tax | -12.84M | -10.22M | -11.56M | -11.56M | 14.88M |
| Income Tax Expenses | 55.00K | 54.00K | 81.50K | 81.50K | 30.00K |
| Earnings from Continuing Operations | -12.90M | -10.27M | -11.64M | -11.64M | 14.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.90M | -10.27M | -11.64M | -11.64M | 14.85M |
| EBIT | -13.42M | -11.45M | -14.20M | -14.20M | 15.05M |
| EBITDA | -13.25M | -11.27M | -14.04M | -14.04M | 15.21M |
| EPS Basic | -0.23 | -0.19 | -0.21 | -0.21 | 0.27 |
| Normalized Basic EPS | -0.14 | -0.12 | -0.14 | -0.14 | 0.18 |
| EPS Diluted | -0.23 | -0.19 | -0.21 | -0.21 | 0.27 |
| Normalized Diluted EPS | -0.14 | -0.12 | -0.14 | -0.14 | 0.18 |
| Average Basic Shares Outstanding | 55.50M | 55.35M | 55.28M | 55.28M | 55.19M |
| Average Diluted Shares Outstanding | 55.50M | 55.35M | 55.28M | 55.28M | 55.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |